Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations

Anemia

Volumn 2015, Issue , 2015, Pages

  Koch, Todd A ^a   Myers, Jennifer ^b   Goodnough, Lawrence Tim ^c  

^a Luitpold Pharmaceuticals Inc   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84938151152     PISSN: 20901267     EISSN: 20901275     Source Type: Journal    
DOI: 10.1155/2015/763576     Document Type: Article

References (62)

1. L. T. Goodnough, "The new age of iron: evaluation andmanagement of iron-restricted erythropoiesis, " Seminars inHematology, vol. 46, no. 4, pp. 325-327, 2009.
2. B. Annibale, G. Capurso, A. Chistolini et al. , "Gastrointestinalcauses of refractory iron deficiency anemia in patients withoutgastrointestinal symptoms, " The American Journal of Medicine, vol. 111, no. 6, pp. 439-445, 2001.
3. P. L. Acher, T. Al-Mishlab, M. Rahman, and T. Bates, "Irondeficiencyanaemia and delay in the diagnosis of colorectalcancer, " Colorectal Disease, vol. 5, no. 2, pp. 145-148, 2003.
4. D. Raje, H. Mukhtar, A. Oshowo, and C. InghamClark, "Whatproportion of patients referred to secondary care with irondeficiency anemia have colon cancer?"Diseases of the Colon andRectum, vol. 50, no. 8, pp. 1211-1214, 2007.
5. M. Auerbach, J. A. Pappadakis, H. Bahrain, S. A. Auerbach, H. Ballard, and N. V. Dahl, "Safety and efficacy of rapidlyadministered (one hour) one gramof lowmolecularweight irondextran (INFeD) for the treatment of iron deficient anemia, "American Journal of Hematology, vol. 86, no. 10, pp. 860-862, 2011.
6. L. T. Goodnough, E. Nemeth, and T. Ganz, "Detection, evaluation, and management of iron-restricted erythropoiesis, " Blood, vol. 116, no. 23, pp. 4754-4761, 2010.
7. M. Auerbach, H. Ballard, J. R. Trout et al. , "Intravenous ironoptimizes the response to recombinant human erythropoietinin cancer patients with chemotherapy-related anemia: amulticenter, open-label, randomized trial, " Journal of ClinicalOncology, vol. 22, no. 7, pp. 1301-1307, 2004.
8. M. Auerbach, "Ferumoxytol as a new, safer, easier-toadministerintravenous iron: yes or no?" The American Journalof Kidney Diseases, vol. 52, no. 5, pp. 826-829, 2008.
9. J. Bonnar, A. Goldberg, and J. A. Smith, "Do pregnant womentake their iron?" The Lancet, vol. 1, no. 7592, pp. 457-458, 1969.
10. G. Weiss and L. T. Goodnough, "Anemia of chronic disease, "TheNew England Journal ofMedicine, vol. 352, no. 10, pp. 1011-1059, 2005.
11. N. C. Andrews, "Anemia of inflammation: the cytokinehepcidinlink, " Journal of Clinical Investigation, vol. 113, no. 9, pp. 1251-1253, 2004.
12. L. T. Goodnough and A. Shander, "Current status of pharmacologictherapies in patient blood management, " Anesthesia &Analgesia;, vol. 116, no. 1, pp. 15-34, 2013.
13. D. H. Henry, N. V. Dahl, M. Auerbach, S. Tchekmedyian, and L. R. Laufmane, "Intravenous ferric gluconate significantlyimproves response to epoetin alfa versus oral iron or noiron in anemic patients with cancer receiving chemotherapy, "Oncologist, vol. 12, no. 2, pp. 231-242, 2007.
14. M. Hedenus, G. Birgegard, P. Nasman et al. , "Addition ofintravenous iron to epoetin beta increases hemoglobin responseand decreases epoetin dose requirement in anemic patients withlymphoproliferative malignancies: a randomized multicenterstudy, " Leukemia, vol. 21, no. 4, pp. 627-632, 2007.
15. L. Bastit, A. Vandebroek, S. Altintas et al. , "Randomized, multicenter, controlled trial comparing the efficacy and safetyof darbepoetin alfa administered every 3 weeks with or withoutintravenous iron in patients with chemotherapy-induced anemia, "Journal of Clinical Oncology, vol. 26, no. 10, pp. 1611-1618, 2008.
16. A. Gafter-Gvili, D. P. Steensma, and M. Auerbach, "Should theASCO/ASHguidelines for the use of intravenous iron in cancerandchemotherapy-induced anemia be updated?" Journal of theNational Comprehensive Cancer Network, vol. 12, no. 5, pp. 657-664, 2014.
17. J. A. Gilreath, D. D. Stenehjem, and G. M. Rodgers, "Diagnosisand treatment of cancer-related anemia, " American Journal ofHematology, vol. 89, no. 2, pp. 203-212, 2014.
18. M. Auerbach, A. S. Liang, and J. Glaspy, "Intravenous iron inchemotherapy and cancer-related anemia, " Community Oncology, vol. 9, no. 9, pp. 289-295, 2012.
19. J. D. Rizzo, M. Brouwers, P. Hurley, J. Seidenfeld, M. R. Somerfield, and S. Temin, "American Society of Clinical Oncology/American Society of Hematology clinical practice guidelineupdate on the use of epoetin and darbepoetin in adultpatients with cancer, " Journal of Oncology Practice, vol. 6, no. 6, pp. 317-320, 2010.
20. D. S. Silverberg, A. Iaina, G. Peer et al. , "Intravenous ironsupplementation for the treatment of the anemia of moderateto severe chronic renal failure patients not receiving dialysis, "American Journal of Kidney Diseases, vol. 27, no. 2, pp. 234-238, 1996.
21. R. S. Hillman and P. A. Henderson, "Control of marrowproduction by the level of iron supply, " Journal of ClinicalInvestigation, vol. 48, no. 3, pp. 454-460, 1969.
22. R. L. Jurado, "Iron, infections, and anemia of inflammation, "Clinical Infectious Diseases, vol. 25, no. 4, pp. 888-895, 1997.
23. K. Bishu and R. Agarwal, "Acute injury with intravenous ironand concerns regarding long-term safety, " Clinical Journal ofthe American Society of Nephrology, supplement 1, pp. S19-S23, 2006.
24. L. T. Goodnough, J. H. Levy, and M. F. Murphy, "Concepts ofblood transfusion in adults, " The Lancet, vol. 381, no. 9880, pp. 1845-1854, 2013.
25. D. R. Spahn and L. T. Goodnough, "Alternatives to bloodtransfusion, " The Lancet, vol. 381, no. 9880, pp. 1855-1865, 2013.
26. L. T. Goodnough, "Blood management: transfusion medicinecomes of age, " The Lancet, vol. 381, no. 9880, pp. 1791-1792, 2013.
27. A. Shander, R. K. Spence, and M. Auerbach, "Can intravenousiron therapy meet the unmet needs created by the newrestrictions on erythropoietic stimulating agents?: report fromthe Society for the Advancement of Blood Management 2008Annual Meeting, " Transfusion, vol. 50, no. 3, pp. 719-732, 2010.
28. M. Auerbach, L. T. Goodnough, D. Picard, and A. Maniatis, "The role of intravenous iron in anemia management andtransfusion avoidance, " Transfusion, vol. 48, no. 5, pp. 988-1000, 2008.
29. G. M. Chertow, P. D. Mason, O. Vaage-Nilsen, and J. Ahlmén, "Update on adverse drug events associated with parenteraliron, " Nephrology Dialysis Transplantation, vol. 21, no. 2, pp. 378-382, 2006.
30. Dexferrum [package insert], American Regent, Shirley, NY, USA, 2008.
31. INFeD, Package Insert, Watson Pharma, Morristown, NJ, USA, 2009.
32. A. M. Ganzoni, "Intravenous iron-dextran: therapeuticand experimental possibilities, " Schweizerische MedizinischeWochenschrift, vol. 100, no. 7, pp. 301-303, 1970.
33. American Regent, Venofer [Package Insert], American Regent, Shirley, NY, USA, 2012.
34. Ferrlecit, Package Insert, Sanofi-Aventis US, Bridgewater, NJ, USA, 2011.
35. Feraheme [package insert], AMAG Pharmaceuticals, Lexington, Mass, USA, 2015.
36. American Regent, Injectafer [Package Insert], American Regent, Shirley, NY, USA, 2013.
37. S. Kulnigg, S. Stoinov, V. Simanenkov et al. , "Anovel intravenousiron formulation for treatment of anemia in inflammatorybowel disease: the ferric carboxymaltose (FERINJECT) randomizedcontrolled trial, " The American Journal of Gastroenterology, vol. 103, no. 5, pp. 1182-1192, 2008.
38. D. B. van Wyck, M. G. Martens, M. H. Seid, J. B. Baker, and A. Mangione, "Intravenous ferric carboxymaltose compared withoral iron in the treatment of postpartum anemia: a randomizedcontrolled trial, " Obstetrics and Gynecology, vol. 110, no. 2, pp. 267-278, 2007.
39. D. B. van Wyck, A. Mangione, J. Morrison, P. E. Hadley, J. A. Jehle, and L. T. Goodnough, "Large-dose intravenous ferriccarboxymaltose injection for iron deficiency anemia in heavyuterine bleeding: a randomized, controlled trial, " Transfusion, vol. 49, no. 12, pp. 2719-2728, 2009.
40. M. H. Seid, R. J. Derman, J. B. Baker, W. Banach, C. Goldberg, and R. Rogers, "Ferric carboxymaltose injection in thetreatment of postpartum iron deficiency anemia: a randomizedcontrolled clinical trial, " American Journal of Obstetrics &Gynecology, vol. 199, no. 4, pp. 435. e1-435. e7, 2008.
41. C. F. Barish, T. Koch, A. Butcher, D. Morris, and D. B. Bregman, "Safety and efficacy of intravenous ferric carboxymaltose(750mg) in the treatment of iron deficiency anemia: tworandomized, controlled trials, " Anemia, vol. 2012, Article ID172104, 9 pages, 2012.
42. I. Hussain, J. Bhoyroo, A. Butcher, T. A. Koch, A. He, andD. B. Bregman, "Direct comparison of the safety and efficacyof ferric carboxymaltose versus iron dextran in patients withiron deficiency anemia, " Anemia, vol. 2013, Article ID 169107, 10 pages, 2013.
43. J. E. Onken, D. B. Bregman, R. A. Harrington et al. , "Amulticenter, randomized, active-controlled study to investigatethe efficacy and safety of intravenous ferric carboxymaltose inpatients with iron deficiency anemia, " Transfusion, vol. 54, no. 2, pp. 306-315, 2014.
44. J. E. Onken, D. B. Bregman, R. A. Harrington et al. , "Ferriccarboxymaltose in patients with iron-deficiency anemia andimpaired renal function: the REPAIR-IDA trial, " NephrologyDialysis Transplantation, vol. 29, no. 4, pp. 833-842, 2014.
45. National Kidney Foundation. KDOQI, "Clinical practice guidelinesand clinical practice recommendations for anemia inchronic kidney disease, " American Journal of Kidney Diseases, vol. 47, supplement 3, pp. S1-S145, 2006.
46. Kidney Disease: Improving Global Outcomes (KDIGO) AnemiaWork Group, "KDIGO clinical practice guideline foranemia in chronic kidney disease, " Kidney International Supplements, vol. 2, no. 4, pp. S279-S335, 2012.
47. National Comprehensive Cancer Network (NCCN), ClinicalPractice Guidelines in Oncology. Cancer-and Chemotherapy-Induced Anemia. Version 2, NCCN, 2015.
48. M. Aapro, A. Osterborg, P. Gascón, H. Ludwig, and Y. Beguin, "Prevalence and management of cancer-related anaemia, irondeficiency and the specific role of I. V. iron, " Annals of Oncology, vol. 23, no. 8, pp. 1954-1962, 2012.
49. C. Gasche, A. Berstad, R. Befrits et al. , "Guidelines on thediagnosis and management of iron deficiency and anemia ininflammatory bowel diseases, " Inflammatory Bowel Diseases, vol. 13, no. 12, pp. 1545-1553, 2007.
50. D. Gozzard, "When is high-dose intravenous iron repletionneeded? Assessing new treatment options, " Drug Design, DevelopmentandTherapy, no. 5, pp. 51-60, 2011.
51. P. Geisser and V. Rumyantsev, "Pharmacodynamics and safetyof ferric carboxymaltose: a multiple-dose study in patientswith iron-deficiency anaemia secondary to a gastrointestinaldisorder, " Arzneimittelforschung, vol. 60, no. 6, pp. 373-385, 2010.
52. R. R. Crichton, B. Danielson, and P. Geisser, Iron Therapy withSpecial Emphasis on Intravenous Administration, UNI-MED, Bremen, Germany, 4th edition, 2008.
53. B. G. Danielson, "Structure, chemistry, and pharmacokineticsof intravenous iron agents, " Journal of the American Society ofNephrology, vol. 15, no. 2, pp. S93-S98, 2004.
54. P. Geisser, M. Baer, and E. Schaub, "Structure/histotoxicityrelationship of parenteral iron preparations, " Drug Research, vol. 42, no. 12, pp. 1439-1452, 1992.
55. S. Beshara, H. Lundqvist, J. Sundin et al. , "Pharmacokineticsand red cell utilization of iron(III) hydroxide-sucrose complexin anaemic patients: a study using positron emission tomography, "British Journal ofHaematology, vol. 104, no. 2, pp. 296-302, 1999.
56. P. Geisser and S. Burckhardt, "The pharmacokinetics andpharmacodynamics of iron preparations, " Pharmaceutics, vol. 3, no. 1, pp. 12-33, 2011.
57. M. Malone, C. Barish, A. He, and D. Bregman, "Comparativereview of the safety and efficacy of ferric carboxymaltose versusstandard medical care for the treatment of iron deficiency anemiain bariatric and gastric surgery patients, " Obesity Surgery, vol. 23, no. 9, pp. 1413-1420, 2013.
58. K. A. Lyseng-Williamson and G. M. Keating, "Ferric carboxymaltose:a review of its use in iron-deficiency anaemia, " Drugs, vol. 69, no. 6, pp. 739-756, 2009.
59. R. Evstatiev, P. Marteau, T. Iqbal et al. , "FERGIcor, a randomizedcontrolled trial on ferric carboxymaltose for iron deficiencyanemia in inflammatory bowel disease, " Gastroenterology, vol. 141, no. 3, pp. 846. e2-853. e2, 2011.
60. X. Calvet, M. A. Rú?z, A. Dosal et al. , "Cost-minimizationanalysis favours intravenous ferric carboxymaltose over ferricsucrose for the ambulatory treatment of severe iron deficiency, "PLoS ONE, vol. 7, no. 9, Article ID e45604, 2012.
61. F. Gomollón and J. P. Gisbert, "Current management of irondeficiency anemia in inflammatory bowel diseases: a practicalguide, " Drugs, vol. 73, no. 16, pp. 1761-1770, 2013.
62. A. A. Khalafallah and A. E. Dennis, "Iron deficiency anaemia inpregnancy and postpartum: pathophysiology and effect of oralversus intravenous iron therapy, " Journal of Pregnancy, vol. 2012, Article ID 630519, 10 pages, 2012.